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Angioedema is defined by non-dependent, non-pitting edema that affects several different sites and 
is potentially life-threatening due to laryngeal edema. This narrative review provides emergency 
physicians with a focused overview of the evaluation and management of angioedema. Two primary 
forms include histamine-mediated and bradykinin-mediated angioedema. Histamine-mediated forms 
present similarly to anaphylaxis, while bradykinin-mediated angioedema presents with greater face 
and oropharyngeal involvement and higher risk of progression. Initial evaluation and management 
should focus on evaluation of the airway, followed by obtaining relevant historical features, including 
family history, medications, and prior episodes. Histamine-mediated angioedema should be treated 
with epinephrine intramuscularly, antihistaminergic medications, and steroids. These medications are 
not effective for bradykinin-mediated forms. Other medications include C1-INH protein replacement, 
kallikrein inhibitor, and bradykinin receptor antagonists. Evidence is controversial concerning the 
efficacy of these medications in an acute episode, and airway management is the most important 
intervention when indicated. Airway intervention may require fiberoptic or video laryngoscopy, with 
preparation for cricothyrotomy. Disposition is dependent on patient’s airway and respiratory status, 
as well as the sites involved. [West J Emerg Med. 2019;20(4)587-600.]
INTRODUCTION
Angioedema is a condition defined by non-dependent, 
non-pitting, transient edema lasting up to seven days due to 
the accumulation of vasoactive substances.1-5 These substances 
increase vascular permeability, resulting in swelling in the deep 
dermal, submucosal, and subcutaneous tissues of the face, 
lips, neck, extremities, and gastrointestinal (GI) system.1,2,6-9 
Urticaria may be present in up to 50% of cases, depending on the 
underlying process.1,2,6-9
Angioedema accounts for 80,000 to 112,000 emergency 
department (ED) visits per year, with a hospitalization rate of 
4.0 per 100,000 population.10-12 For patients taking angiotensin-
converting enzyme inhibitors (ACEi), the incidence of 
angioedema ranges from 0.1-0.7% over a patient’s lifetime, 
while the prevalence of hereditary angioedema (HAE) ranges 
from 1 in 10,000 to 1 in 50,000 persons.6,10-15  Over 50% of 
patients with HAE require ED management, with over half of 
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patients admitted to the hospital.1-3 ACEi-mediated angioedema 
accounts for 30% of angioedema cases. Of the cases of ACEi-
mediated angioedema, one study found 18% of patients were 
admitted to observation, 12% to the inpatient setting, and 11% 
to the intensive care unit.1,16 Due to risk of airway involvement 
and death, the emergency physician (EP) plays a key role in 
assessment and management of angioedema.1,2,17,18
METHODS
We searched PubMed and Google Scholar for articles 
in English from 1966 to October 2018 using a combination 
of the keyword and medical subject heading “angioedema” 
for production of this narrative review. Our search included 
case reports and series, retrospective and prospective studies, 
systematic reviews and meta-analyses, narrative reviews, and 
clinical guidelines. Two authors decided by consensus which 
studies to include for the review. Initial literature search revealed 
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Population Health Research Capsule
What do we already know about this issue?
Angioedema is defined by non-dependent, non-pitting 
edema that affects several different sites and is 
potentially life-threatening due to laryngeal edema.
What was the research question?
This narrative review evaluates the pathophysiology, 
evaluation, and management of angioedema.
What was the major finding of the study?
There are two forms of angioedema. Management 
must focus on the airway, although several 
medications are promising.
How does this improve population health?
Evidence is controversial for the efficacy of several 
medications, and airway management is the most 
vital intervention if indicated. Disposition depends 
upon airway and respiratory status.
over 500 articles, of which 185 were selected for inclusion, 
focusing on ED evaluation and management.
DISCUSSION
Etiology
Angioedema can be defined as either hereditary 
(bradykinin) or acquired (bradykinin or histamine) (Table 1).1-
5,7,15,19-24 The underlying pathophysiology (ie, bradykinin- vs 
histamine-mediated) influences the clinical presentation and 
treatment recommendations.1,2,7,8 Bradykinin-mediated forms are 
generally more severe, longer lasting, and frequently involve the 
upper airway and gastrointestinal (GI) system.1,20-24 
Histamine-mediated
Histamine-mediated angioedema is the most common 
form, accounting for 40-70% of all cases, and is associated 
with immunoglobulin E resulting in degranulation of mast 
cells and basophils.1-5 H1 and H2 receptors are primarily 
responsible for the swelling that leads to angioedema.1,4,5 
Histamine-mediated angioedema, such as anaphylaxis, occurs 
rapidly after an allergen exposure (type I hypersensitivity 
reaction).5,25-30 Histamine-mediated angioedema and 
anaphylaxis present similarly, as they are along the same 
clinical spectrum, although diagnosis of anaphylaxis requires 
specific clinical criteria.1-5 Importantly, therapy for histamine-
mediated angioedema and anaphylaxis is the same, which 
will be discussed later. Histamine-mediated angioedema 
typically resolves within 24-48 hours. This form can result 
from food allergens, medications, exercise, bites, stings, or 
latex exposure.31-33  There is also a form of physically-induced 
angioedema from cold exposure, heat pressure, physical 
activity, ultraviolet radiation, and vibration, which is most 
likely due to histamine release.34-36 
Bradykinin-mediated
Bradykinin-mediated pathways involve this vasoactive 
nonapeptide that activates endothelial cells.5,14,37 Several systems 
regulate bradykinin, including the coagulation, complement, and 
contact pathways.4,38 Excess bradykinin is due to  production, 
release, or inhibition of its breakdown.39-41 This form comprises 
drug-induced angioedema (ie, ACEi-mediated), HAE 
Types Characteristics
Histamine-mediated 
(with urticaria)
- Allergy to food, venom, latex, medication
- Acute or chronic spontaneous urticaria
- Urticaria/angioedema associated with cold urticaria, vasculitis, exercise, episodic angioedema, 
vibration-induced, drug reactionp
Bradykinin-mediated 
(without urticaria)
- Type I HAE: defective C1-INH level/function
- Type II HAE: defective C1-INH function
- Type III HAE: normal C1-INH 
-Acquired C1-INH deficiency: Type I associated with increased catabolism of C1-INH 
(lymphoproliferative disorder, autoimmune disease); Type II associated with autoantibody to C1-INH
- ACEi-mediated angioedema
- Medication associated: dipeptidyl peptidase-IV inhibitor (gliptins for diabetes mellitus), angiotensin II 
receptor blockers, recombinant tissue plasminogen activator, sirolimus, tacrolimus, everolimusd
Idiopathic 
(unknown etiology)
- Histaminergic
- Nonhistaminergic
HAE, hereditary angioedema; C1-INH, C1 inhibitor; ACEi, angiotensin-converting enzyme inhibitor.
Table 1. Types of angioedema.
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types I and II, and several forms of acquired and idiopathic 
angioedema.13,20,42,43 
ACEi-mediated angioedema accounts for up to 30% of 
ED visits for angioedema of all types.16,21,44-49 ACEis prevent 
the conversion of angiotensin I to angiotensin II and reduce 
bradykinin metabolism, which increases the risk of angioedema. 
Most cases are localized to the lips and tongue.14,15 Patients at 
greatest risk for developing ACEi-mediated angioedema include 
African Americans and those taking immunosuppressants 
or dipeptidyl peptidase-IV inhibitors (a class of diabetic 
medications) in addition to the ACEi.14,15,49  The rate of 
angioedema is highest within the first 30 days of starting an 
ACEi, although the risk of angioedema remains for the duration 
of the ACEi use, with cases of ACEi-mediated angioedema 
documented in patients with prolonged courses of multiple 
years.50-52 If a patient continues taking an ACEi after developing 
ACEi-mediated angioedema, the average time to recurrence is 
approximately 10 months.50,53 Angiotensin II receptor blockers 
(ARB) and renin antagonists can also cause angioedema, but this 
is not due to bradykinin.1-5 If angioedema develops in a patient 
on an ACEi, the ACEi should be discontinued and a different 
antihypertensive class used.
HAE is thought to be autosomal dominant with abnormal 
C1-INH amounts and/or function. HAE affects approximately 
1 in 10,000–50,000 people.1,2,54,55 Type 1 is due to decreased 
and defective C1-INH and is the most common (85%) form of 
HAE, followed by type II which is caused by dysfunctional C1-
INH.13,55-59 A third form of HAE with normal C1-INH has also 
been described.60-62 Most patients present by age 10 with recurrent 
episodes of edema.1-4,58  HAE is often associated with prodromal 
symptoms, such as erythema marginatum, but not urticaria.1,4,16,61,63 
HAE occurs more commonly in females and causes more severe 
swelling with significant face and tongue involvement when 
compared with males.1-5,13 Estrogen-containing medications and 
pregnancy increase the attack frequency in female patients.7,61,64 
Acquired angioedema appears similar to HAE with C1-
INH deficiency, but this is not hereditary and more commonly 
affects those > 40 years.1,65-71 This form is most commonly due 
to catabolism of C1-INH, although some patients may have a 
lymphoproliferative or autoimmune disorder.1,65-71  
A less common cause of non-histaminergic angioedema 
is associated with medications, including nonsteroidal anti-
inflammatory drugs (NSAID), antibiotics, and ARB.72-75 
NSAID-associated angioedema results from inhibition of 
cyclooxygenase and accumulation of leukotriene mediators, 
and occurs in 0.1-0.3% of patients taking an NSAID.56 
Exposure to recombinant tissue plasminogen activator therapy 
in acute ischemic stroke is also associated with angioedema, 
occurring in 1.2-5.1% of patients, with increased risk in 
patients taking an ACEi.76-80 Most of these cases are mild and 
resolve in 24 hours.1,2,7,8
Idiopathic
Idiopathic angioedema is diagnosed by failure to determine 
the etiology with > 3 attacks in a 6-12 month period.2,5,81-83 
Most patients with idiopathic angioedema will demonstrate a 
response to standard therapies for anaphylaxis (eg, epinephrine, 
antihistamines, steroids), although a small group will not 
improve with these therapies.1-4,84 This latter group is more 
commonly bradykinin-associated.1-4,84   
Presentation, History, and Physical Examination
Initial evaluation requires assessing vital signs, airway, and 
cardiovascular systems. Asphyxiation is the leading cause of 
mortality in these patients, necessitating airway evaluation.17,18,85 
At least one episode of laryngeal edema occurs in over half of 
all patients with HAE and accounts for over 30% of deaths in 
HAE.17,18  Emergency physicians (EP) must inquire about lip 
swelling, tongue swelling, and GI symptoms (nausea, vomiting, 
diarrhea, and pain).  Additional information to gather includes 
prior personal or family history of angioedema, medications, 
and related symptoms (eg, pruritis, dyspnea, syncope, 
lightheadedness).85-93 Patients with a known history of HAE 
should also be asked about recent trauma, which can trigger an 
episode.1-5 Most patients with HAE report prodromal symptoms 
prior to swelling, such as fatigue and rash.94 
The presentation can vary depending upon the subtype 
but is primarily dependent upon whether the etiology is 
histaminergic or non-histaminergic (Table 2).1-5,13 The most 
commonly involved areas include the head and neck (eg, 
eyelids, lips, tongue, larynx), extremities (eg, hands and feet), 
external urogenital system, and abdomen.1-5,9,13,28 However, 
involvement of these sites is often non-contiguous, with no 
specific pattern.1-5,7,8 Histaminergic forms display faster onset, 
while HAE and acquired forms have a slower, progressive 
onset occurring over several hours.1,2,7,8  GI tract submucosal 
involvement occurs in up to 93% of patients with HAE and 
can cause symptoms that mimic bowel obstruction.13,55,90,91 
Non-pitting edema is present in both histaminergic and non-
histaminergic forms.1,4,7,8 Pruritic, localized, urticarial lesions 
may be present in histamine-mediated forms with involvement 
Features Histaminergic Non-histaminergic
Onset Minutes Hours
Duration 12-24 hours 48-72 hours
Hypotension Common Atypical
Urticaria Common Atypical
Bronchospasm; wheez-
ing
Common Atypical
Laryngeal edema Possible Possible
Abdominal pain Possible Possible
Therapy with epinephrine, 
antihistamines, steroids
Effective Not effective
Table 2. Comparison of features between non-histaminergic and 
histaminergic angioedema.
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of the deep dermis, but these are rare in non-histaminergic 
forms.13,95,96 Urticaria occurs in approximately 50% of patients 
with histamine-mediated angioedema.13,95,96 
Findings suggestive of the need for a definitive airway 
include stridor, hoarseness, dyspnea, and voice changes.86-92 
The patient should be asked to phonate “E” with a high pitch, 
as a patient able to complete this maneuver is unlikely to have 
laryngeal edema.1,7,8  Auscultation of the lungs to determine the 
presence of wheezing is recommended.
Differentiating histamine and bradykinin-mediated 
angioedema can be difficult. One retrospective study evaluated 
188 patients, with one point assigned to age > 65 years, dyspnea, 
no itching or erythema, laryngeal involvement, and intake of 
ACEi/AT-II antagonist, and two points assigned if there was 
no response to steroid therapy.97 If the score was > 3 points, the 
patient was treated with C1-INH or B2 receptor antagonist for 
suspicion of bradykinin-mediated angioedema. This resulted 
in a sensitivity of 96% and specificity of 84% for the diagnosis 
of bradykinin-mediated angioedema.97 While this tool can 
help to differentiate the underlying etiology, it requires further 
validation before routine use. 
Diagnostic Testing
Angioedema is a clinical diagnosis, with no required testing 
in the ED.1,2,4  Leukocyte counts cannot reliably differentiate if 
an infection is present, as leukocytosis over 30,000 per cubic 
millimeter has been observed.98 C-reactive protein may be 
elevated in ACEi-mediated angioedema.1,4 Determining the 
specific type of angioedema involves specialized laboratory 
testing not available in the ED, including tryptase, C4, and C1-
INH.1-4 These tests can be obtained in the outpatient setting and 
should not be routinely obtained in the ED, as they do not guide 
management. Histamine-mediated forms can display elevated 
tryptase levels during attacks, while patients with HAE will 
display normal tryptase levels.3 C4 levels serve as a sensitive 
screening test for C1-INH deficiency.1,3 Serum C4 levels will 
typically be < 30% of normal in acute episodes of angioedema 
from HAE types I and II, although the laboratory values may 
be normal between attacks.23,100,101 Type I HAE often involves 
low C1-INH levels and decreased function, while type II HAE 
includes normal levels but decreased function.13,19,102  C1q 
levels, a component of the complement system, can be used to 
differentiate acquired and hereditary forms, as C1q is decreased 
in acquired angioedema and normal in HAE.1,3,4,100,103 Type III 
HAE has normal levels and function of C1-INH but is usually 
identified by a positive family history.1-4,7,8 No tests can confirm 
ACEi-mediated angioedema.1,7,19,23 
Patients with abdominal symptoms may demonstrate 
segmental bowel wall edema, straightening of intestinal 
segments, and ascites on computed tomography (CT).4,104,105  
Ultrasound may similarly reveal bowel wall thickening or 
ascites.106 Ultrasound can be used to evaluate for laryngeal 
edema, although this requires further study.4 Chest radiography, 
if obtained, is typically normal. Neck radiographs and CT of 
the neck with intravenous (IV) contrast can evaluate for mimics 
of angioedema, but they should not be ordered routinely for 
patients with suspected angioedema.104 Fiberoptic visualization 
of laryngeal and airway structures is recommended if concern for 
laryngeal or airway involvement is present.
Management
The primary focus of ED management is assessment 
of the airway and evaluation for anaphylaxis, which is the 
most common mimic.1-4,7,8 Figure 1 depicts an algorithm for 
management. Vital signs should not be relied upon in isolation to 
determine the need for airway intervention.  
Airway Management
Patients with angioedema involving the tongue or larynx 
require consideration of definitive airway management. 
Angioedema can progress rapidly within hours, and 
airway obstruction occurs in up to 15% of patients with 
angioedema.1,4,17,18 For patients with angioedema who require a 
definitive airway, cricothyrotomy or tracheostomy is needed in 
up to 50% of cases.17,87,105 Prior history of intubation or severe 
angioedema should raise the concern for a difficult airway which 
may require early airway intervention.1,4,107 Evidence of upper 
airway involvement on examination includes stridor, change in 
patient voice, and hoarseness. If physical examination reveals 
swelling of the tongue, floor of the mouth, or soft palate, directly 
visualize the tongue base and airway with fiberoptics. The 
presence of epiglottic, aryepiglottic, or laryngeal edema suggests 
need for definitive airway.1,2 If the angioedema exclusively 
involves structures anterior to the teeth such as the lips, intubation 
is generally not needed.85-92
Noninvasive positive pressure ventilation can also assist 
with temporization; however, this is not a definitive therapy for 
patients with airway involvement. Supraglottic and extraglottic 
airway devices are common rescue devices; however, they are 
not recommended in patients with angioedema, as the device will 
remain above the site of airway obstruction.1,4,7,8,85 If placed, these 
devices may also worsen edema due to the associated trauma 
with placement. 
Physical manipulation of the airway may worsen edema, 
especially in bradykinin-mediated angioedema.1,4,7,8 In 
patients with history or evidence on examination of a difficult 
airway, video laryngoscopy or fiberoptic awake intubation is 
recommended, as this allows the patient to maintain his/her 
airway reflexes during airway visualization and the intubation 
attempt.1,4,107-109 Topical anesthetics and ketamine are optimal 
agents for awake intubation. Severe edema may prohibit 
passage of an endotracheal tube through the glottis, even with 
the use of fiberoptic or video laryngoscopy guidance. Thus, the 
resuscitation team must prepare for cricothyrotomy before an 
attempt at intubation is started, known as a double setup.1-5 If the 
patient does not require immediate airway intervention, transfer 
to the operating room may be beneficial with anesthesia and 
otolaryngology consultation, similar to pediatric epiglottitis. 
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Figure 1. Algorithm for angioedema management. 
IV, intravenous; IM, intramuscular; ACEi, angiotensin converting enzyme inhibitor; FFP, fresh frozen plasma; ICU, intensive care unit.
*ACEi-mediated, Hereditary, or Acquired Angioedma only.
**Hereditary or Acquired Angioedema only.
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Medications
Medication management focuses on three aspects: acute 
episode management, short-term prophylaxis, and long-term 
prophylaxis, with ED management focusing on the acute 
episode.1,4,7,8 If the suspected etiology is drug- or allergic-induced, 
the trigger must be removed.1-5 In histamine-mediated forms of 
angioedema, standard therapy for anaphylaxis is recommended. 
However, in other forms of angioedema including bradykinin-
mediated forms, standard therapies for anaphylaxis should not be 
effective.110,111  
Patients with evidence of histaminergic forms of angioedema 
and concern for airway involvement should receive epinephrine, 
steroids, antihistamines, and IV fluids.1-5,7,8,112 If there is any 
suspicion of anaphylaxis, urticaria-associated angioedema, or 
if the exact underlying cause of the angioedema is unknown, 
histamine-mediated edema should be assumed. Epinephrine 
should be administered via the intramuscular route into the 
anterolateral middle third of the thigh, with initial dose 0.3-
0.5 milliliter (mL) (0.3-0.5 milligram [mg]) of 1:1000 dilution 
(1 mg/mL), which can be repeated every 5-20 minutes.1,4 
Subcutaneous administration is not recommended.112-114 IV 
epinephrine should be considered in patients requiring multiple 
doses of intramuscular epinephrine and should begin at doses of 
1-4 micrograms (mcg) per minute.112,115,116  Epinephrine can be 
administered peripherally by injecting 1 mg of epinephrine into 
1 L of normal saline, resulting in a final concentration of 1 mcg/
mL. If administered wide-open through an 18-gauge IV, this 
provides 20-30 mL/minute (20-30 mcg/minute) of epinephrine. 
Adjunctive therapies for histamine-mediated angioedema 
include antihistamines and steroids.1-5,7,8,112 Antihistamines have a 
slower onset of action and should only be used as an adjunctive 
therapy.1-5,7,8,112,117 Diphenhydramine is an H1 antagonist that 
can be used in doses of 25-50 mg IV to reduce swelling in 
combination with a second- or third-generation antihistamine 
agent (eg, cetirizine, loratadine, fexofenadine, levocetirizine, 
desloratadine).1-5,112,117-127 The addition of an H2 antagonist is 
beneficial in decreasing urticaria, as 15% of cutaneous histamine 
receptors are H2.117-128 Steroids such as methylprednisolone 125 
mg IV decrease inflammatory mediators in histamine-mediated 
angioedema and anaphylaxis but, similar to other medications, 
there is little to no evidence for their use in non-histaminergic 
angioedema.1,4,7,8,112 The onset of action after administration is 
delayed, typically requiring 4-6 hours to take effect.1-5,7,8,14,15 
Fresh frozen plasma (FFP) has been recommended for use in 
angioedema based on case reports demonstrating improvement 
in HAE and ACEi-mediated angioedema,129-133 as FFP contains 
varying amounts of C1-INH.1-4,7,8,14,15,134-136 Several of the first 
case reports suggested FFP can be used as prophylaxis for HAE 
in patients undergoing dental procedures.129,135,137 A retrospective 
study suggests efficacy in decreased intubation frequency and 
intensive care unit (ICU) length of stay.137 However, type II HAE 
may worsen with FFP due to the presence of an autoantibody 
responsible for decreased C1-INH.134 Limited literature has 
described FFP in ACEi-mediated angioedema, primarily case 
reports and series demonstrating improved symptoms at four 
hours.132,133,136,138-145 Its use in acquired forms has not demonstrated 
efficacy, and a major limitation is the need to thaw FFP for 
use. The literature is inconsistent with regard to preferred 
dosing, with most studies giving 1-4 units (250–1000 cubic 
centimeters).1-5,135,136 FFP requires close to 50 times the volume of 
other medications with C1INH to obtain the same serum levels of 
enzyme.135 Risks include potential volume overload, transmission 
of bloodborne infection, and hypersensitivity reaction.1-4,7,8,136 FFP 
also contains substrates such as kallikrein and kininogen that may 
paradoxically worsen angioedema.1-4,7,8,14 Despite this theoretical 
effect, worsening of angioedema with FFP administration has not 
been found in cases of ACEi-mediated angioedema.1,4,134-136 There 
is no support for FFP in other acquired forms of angioedema.1-4,135 
Prothrombin complex concentrate (PCC) has also been 
used for ACEi-mediated angioedema.1,4,146 However, the data is 
limited to one case report in which 1500 units were administered. 
Symptoms began to improve in 20 minutes, with resolution in 
eight hours.146 Four-factor PCC contains C1-INH, which may 
explain the improved symptoms. 
Targeted Therapies for Bradykinin-mediated Angioedema
Bradykinin-mediated forms of angioedema are typically 
resistant to therapies effective in histamine-mediated 
reactions.1,4,7,8,13,135,136,147 At the time of construction for this 
review, several medications have been FDA approved for 
treatment of acute bradykinin-mediated angioedema: three C1-
INH concentrates (two plasma-derived and one recombinant), 
one kallikrein inhibitor, and one bradykinin-2-receptor 
antagonist (Table 3).1,4,7,8,13,135,136  
C1 Inhibitor Concentrate
C1-INH concentrate for HAE episodes was first described 
in 1973, and there are two plasma-derived formulations currently 
available (Berinert and Cinryze), as well as one recombinant form 
(Ruconest), all administered intravenously.1-5,7,8,135,136,148 They are 
currently approved for acute HAE, although these medications 
have been used for ACEi-mediated forms.1-5,7,8,135,136,148 Berinert 
and Cinryze provide native plasma protein that regulates 
kallikrein and Factor XII activity, reducing bradykinin 
production. Bork et al. published a study based on 18 patients 
with 193 episodes of HAE, finding that the mean time to 
reversal was 42.2 minutes.149 The IMPACT trials (funded by 
CSL Behring, manufacturer of Berinert) evaluated Berinert vs 
placebo for acute episodes of HAE. IMPACT-1 found 20 units 
per kilogram (kg) improved time to symptom relief (0.5 hours 
vs 1.5 hours), but 10 units/kg did not.150,151 IMPACT-2 evaluated 
1085 episodes of HAE in 57 patients, with a median time to 
symptom relief of 0.46 hours in patients receiving open-label 
Berinert.151 Cinryze has also been evaluated in HAE, with a 
double-blind placebo-controlled trial of 68 patients finding no 
statistically significant improvement in time to relief, although a 
double-blind crossover trial of 21 patients demonstrated decrease 
in attack number, duration, and severity.4,136,152 A study that was 
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not placebo controlled found 68% of patients had improvement 
at one hour, while 87% experienced relief at four hours.153 Other 
trials evaluating Berinert and Cinryze for HAE and ACEi-
mediated angioedema have found that the time to symptom 
improvement from administration varies from 0.5-5 hours, with 
complete resolution occurring within 1-10 hours.136 Ruconest is 
a recombinant form of C1INH. One open-label study with no 
placebo control found time to symptom relief of 30 minutes.154 
A double-blind, placebo-controlled trial found time to symptom 
relief of 66 minutes in patients receiving 100 units/kg, vs 495 
minutes in controls.155 Another randomized trial found time to 
symptom relief of 75 minutes in treated patients vs 303 minutes 
in patients receiving placebo.156 
Kallikrein Inhibitor
Ecallantide (Kalbitor) is a recombinant plasma inhibitor 
of kallikrein provided subcutaneously and approved for use 
in HAE.1,4,7,8,136 This agent reduces bradykinin synthesis by 
preventing the cleavage of kininogen.1,4,7,8,136 It is associated with 
up to a 3% risk of anaphylaxis, necessitating close observation 
during administration and for up to one hour after.1,4,7,8 The 
EDEMA trials evaluated ecallantide for HAE.157-160 The 
EDEMA1 trial evaluated ecallantide at various doses vs placebo, 
finding the 40 mg/m2 dose improved symptoms at four hours, 
although other doses did not.157 The phase 2 EDEMA2 trial found 
subcutaneous dosing had improved outcomes vs IV dosing.158 
EDEMA3 was an open label and double-blind phase 3 trial 
evaluating ecallantide vs placebo, with improvement in treatment 
score at four hours in patients receiving ecallantide.159 EDEMA4 
found improved symptom scores vs placebo.160 A triple-blind 
phase 2 randomized controlled trial compared ecallantide at three 
different subcutaneous doses with placebo for ACEi-mediated 
angioedema and found no difference in patients meeting criteria 
for discharge.161 Lewis et al. conducted a double-blind phase 2 
study with patients randomized to placebo or ecallantide.162 Most 
patients received therapy for histamine-mediated angioedema as 
well. The study found no difference in patients meeting criteria 
for discharge within six hours with ecallantide administration.162 
Bradykinin B2 Receptor Antagonist
Icatibant acetate (Firazyr) is a selective and competitive 
bradykinin B2 receptor antagonist.1,4,7,8,136 Icatibant was evaluated 
in three clinical trials: FAST-1, FAST-2, and FAST-3.136,163,164 
FAST-1 was a double-blind, placebo-controlled trial that 
demonstrated faster symptom relief (0.8 vs 16.9 hours) but no 
difference in the degree of symptom relief.4,163 The FAST-2 study 
demonstrated improved time to symptom relief in a double-
blind study comparing icatibant to oral tranexamic acid (onset of 
symptom improvement 0.9 vs 7.8 hours).4,163 FAST-3 was a phase 
3 double-blind, randomized, placebo-controlled trial that found 
a decrease in the time to primary symptom relief (2.0 vs 19.8 
hours) and complete symptom relief (median 8.0 vs 36 hours).4,164 
The literature suggests that the time to symptom improvement 
ranges from several minutes up to seven hours for icatibant. Of 
studies reporting improvement, approximately half of patients 
improve within 30 minutes, while time to complete symptom 
resolution ranges from 0.5-16 hours.136,165-174 Importantly, 40% of 
cases have complete resolution under four hours.136,165-173   A phase 
2 multicenter, randomized controlled trial by Bas et al. evaluated 
icatibant vs steroids plus antihistamines, finding a shorter time 
to symptom relief with icatibant (2 hours vs 11.7 hours).174 More 
patients receiving icatibant also demonstrated resolution of edema 
at four hours. However, there was no difference in the degree of 
patient-reported symptom relief.4,136 
Medication (trade name) Mechanism Route Dose Time to onset Minor side effects Serious side effects
Plasma derived C1-INH 
(Berinert, Cinryze)
C1-INH protein 
replacement
IV Berinert 
20 units/
kg; Cinryze 
1000 units
Median 30-48 
minutes
Dysgeusia Hypersensitivity, 
thrombosis, blood-
borne infection
Recombinant C1-INH 
(Ruconest)
C1-INH protein 
replacement
IV 50 units/kg Median 90 
minutes
Pruritis, rash, 
sinusitis
Hypersensitivity, 
anaphylaxis
Ecallantide (Kalbitor) Kallikrein inhibitor SQ 30 mg Median 67 
minutes
Headache, injection 
site reactions, 
nausea, fever
Hypersensitivity, 
anaphylaxis
Icatibant acetate 
(Firazyr)
Bradykinin 
B2 receptor 
antagonist
SQ 30 mg Median 2 
hours
Elevated LFTs, 
injection reaction, 
dizziness, headache, 
nausea, fever
Theoretical worsening 
of an ongoing ischemic 
event
Fresh frozen plasma C1-INH protein 
replacement 
(various amounts)
IV 15 mg/kg Minutes to 
hours
Hypersensitivity, 
worsening angioedema, 
transfusion infection
Table 3. Angioedema medications.
C1-INH, C1 inhibitor; IV, intravenous; SQ, subcutaneous; LFTs, liver function tests; mg, milligram; kg, kilogram.
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A systematic review published in 2017 evaluating medication 
use in ACEi-mediated angioedema concluded icatibant possessed 
the highest level of evidence due to better study quality, while 
FFP has limited evidence demonstrating benefit and inconsistent 
dosing strategies for ACEi-mediated angioedema.136 This 
systematic review incorporated case reports, case series, a 
prospective observational study, and one randomized controlled 
trial. However, the recommendations were limited by low 
quality evidence and significant heterogeneity with respect to 
the severity of angioedema and clinical outcomes.175 Most of the 
included studies evaluated time to discharge and time to symptom 
relief, rather than the need for definitive airway, peak symptoms 
severity, duration of mechanical ventilation, and hospital/
ICU admission.136,175 Publication bias was also severe, limiting 
conclusions. Studies following the publication of this systematic 
review from 2017 suggest no difference in time to discharge 
with icatibant.175 Sinert et al. evaluated icatibant vs placebo in 
a phase III, double-blind clinical trial.176 Time to discharge was 
four hours in both groups, with similar time of symptom relief.176 
A second prospective, randomized study published by Straka 
et al. compared icatibant and placebo, finding no difference in 
symptom severity or duration.177 
The current literature evaluating targeted therapy for 
bradykinin-mediated angioedema suffers from several limitations, 
including significant heterogeneity in patient selection, outcomes, 
comparators, dosing, and study design, as well as low numbers 
of included patients and high risk of bias.1,4,136,175 Medication 
efficacy is controversial with delayed onset of action, variable 
relief of symptoms, and limited availability depending on the 
institution.136,175 Rather than primarily focus on administering 
medications that may or may not improve symptoms in 
bradykinin-mediated forms of angioedema, EPs should focus on 
managing the patient’s airway.1,4,175
Disposition
Disposition is mainly determined by airway involvement. 
Several studies have sought to predict airway compromise in 
patients with acute angioedema.1-5,85,178 Ishoo et al. performed 
a retrospective study of 80 patients with 93 acute episodes 
of angioedema.85 Wheezing, voice change, hoarseness, and 
stridor predicted the need for airway intervention. This 
study categorized patients based on the anatomic location of 
angioedema (Table 4).85 A subsequent study published one 
year later found the same factors predict need for definitive 
airway.178 Importantly, these factors require further validation 
and laryngeal visualization for staging. 
Patients with respiratory or airway distress require ICU 
admission, as well as those with stage III and IV edema due 
to risk of progression.1-5,7,8,89 Patients with stable or improving 
stage I or II edema of the face, lip, or soft palate should be 
monitored for several hours to evaluate for worsening of the 
angioedema.1-5,7,8,89,102 Patients with stage I angioedema can be 
discharged with follow-up after evaluation for progression. 
Patients with stage II angioedema are often discharged home 
within 24 hours, and ED observation units provide an optimal 
setting for monitoring of these patients.1,4 However, if edema 
involves > 3 sites (lips, tongue, mouth floor, soft palate, and 
larynx), admission is recommended due to greater risk of 
airway involvement.89 
Patients with acute and recurrent angioedema may benefit 
from consultation with allergy/immunology specialists to discuss 
laboratory testing and arrange follow-up, particularly in patients 
with HAE.1-5,7,8,102 Patients with a first episode of angioedema, 
no response to anaphylaxis treatment, or family history of HAE 
require follow-up with an allergy/immunology specialist. These 
specialists can help diagnose a specific cause, evaluate and 
educate the patient concerning triggers, and provide prophylactic 
medications, which may prevent the need for ED care.1,4,179,180 
Patients with known HAE and a recurrent attack may present 
with an action plan and recommended therapies, which should be 
followed when possible.102,181,182
Patients discharged from the ED with histamine-mediated 
angioedema and those with unclear etiology or first-time episode 
should be prescribed epinephrine autoinjectors and educated on 
potential triggers.69,102 Family and friends should also be educated 
on these factors. Patients with respiratory distress or airway 
swelling after discharge should use the epinephrine autoinjector 
and immediately return to the ED. The patient with ACEi-
mediated angioedema must discontinue his or her medication, 
and an alternative agent should be discussed with the patient’s 
primary care provider.1-5,7,8,102  Most patients can use calcium 
channel blockers or angiotensin receptor blockers without 
developing a recurrence of their angioedema.1,183,184 The literature 
suggests the incidence of angioedema with ARB is 0.11%, which 
is not statistically different than placebo.185 
Stage Site Frequency Discharge Inpatient ICU Intervention
I Face, lip 31% 48% 52% 0% 0%
II Soft palate 5% 60% 40% 0% 0%
III Tongue 32% 26% 7% 67% 7%
IV Larynx 31% 0% 0% 100% 24%
Table 4. Predicting airway compromise based on anatomic location of angioedema.85 
ICU, intensive care unit.
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CONCLUSION
Angioedema is non-dependent, non-pitting edema at a 
variety of sites. Its forms can be divided into histamine-mediated 
and bradykinin-mediated types. Histamine-mediated forms can 
present similarly to anaphylaxis, while bradykinin-mediated 
angioedema is slower in onset, presents with greater face and 
oropharyngeal involvement, and has higher risk of progression. 
Initial evaluation and management should focus on the airway, 
followed by an evaluation for family history, medications, and 
prior episodes. Histamine-mediated angioedema is treated like 
anaphylaxis with epinephrine, antihistamines, and steroids. 
These medications are not effective for the bradykinin-mediated 
forms, although they can be attempted in the absence of effective 
therapy. Other medications include C1-INH protein replacement, 
kallikrein inhibitor, and bradykinin receptor antagonists. Several 
studies have evaluated these for angioedema, but the evidence is 
lacking for efficacy. The focus should be on airway management 
rather than medications in bradykinin-mediated angioedema. This 
may require fiberoptic or video laryngoscopy, with preparation 
for cricothyrotomy. Disposition depends on patient’s airway and 
respiratory status, as well as the involved sites. 
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